Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
|Articles|June 10, 2022
Daily Medication Pearl: Tolvaptan (Jynarque)
Author(s)Saro Arakelians, PharmD
Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist .
Advertisement
Indication: Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease. It is also used to treat hyponatremia in patients with heart failure or syndrome of inappropriate antidiuretic hormone.
Insight:
- Dosing: May range from 15 mg to 120 mg, based on the initial titration or target dosage.
- Dosage forms: Tablets 15 mg, 30 mg, 45 mg, 60 mg and 90 mg .
- Adverse events: Most common observed adverse reactions with tolvaptan (incidence >10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria, and polydipsia.
- Mechanism of action: Tolvaptan is a selective vasopressin V2-receptor antagonist with an affinity for the V2-receptor that is 1.8 times that of native arginine vasopressin.
Source:
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
4
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
5